Xtant Medical Holdings, Inc.
AMEX:XTNT · New York Stock Exchange American
-$0.00 today
Vol 0.06M · Avg 0.16M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
AMEX:XTNT · Revenue to Net Income
Key Ratios
Analysis
$121.9M of revenue converted into $1.8M of net income for the selected period. Gross margin is 61.7% and net margin is -0.2%, showing how much revenue survives after costs and taxes. EPS is $0.01, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $133.9M +14.2% | $117.3M +28.4% | $91.3M +57.5% | $58.0M +4.9% | $55.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $49.7M +1.2% | $49.1M +36.9% | $35.8M +38.7% | $25.8M +13.4% | $22.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $84.3M +23.5% | $68.2M +23.0% | $55.5M +72.6% | $32.1M -1.1% | $32.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 62.9% +4.8pp | 58.2% -2.6pp | 60.8% +5.3pp | 55.4% -3.4pp | 58.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $2.1M -11.9% | $2.4M +78.5% | $1.3M +46.0% | $915.0K +5.2% | $870.0K | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $74.9M -3.9% | $77.9M +21.2% | $64.3M +69.3% | $38.0M +7.1% | $35.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $77.0M -4.1% | $80.3M +22.3% | $65.6M +68.7% | $38.9M +7.0% | $36.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $5.2M +23.7% | $4.2M +33.1% | $3.2M +144.9% | $1.3M -3.4% | $1.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | $15.9M +301.8% | -$7.9M -255.2% | $5.1M +193.5% | -$5.4M -116.0% | -$2.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 11.9% +18.6pp | -6.7% -12.3pp | 5.6% +14.9pp | -9.4% -4.8pp | -4.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $7.3M +160.3% | -$12.1M -18.9% | -$10.2M -50.4% | -$6.8M -75.3% | -$3.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 5.4% +15.7pp | -10.3% +0.8pp | -11.1% +0.5pp | -11.7% -4.7pp | -7.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $94.0K | $0 -100.0% | $149.0K +380.6% | $31.0K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $3.7M -11.8% | $4.2M +41.6% | $2.9M +73.6% | $1.7M +70.1% | $995.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$283.0K +93.2% | -$4.2M -145.9% | $9.1M +649.1% | -$1.7M -66.9% | -$995.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $7.0M +143.1% | -$16.3M -1468.2% | -$1.0M +87.7% | -$8.4M -73.6% | -$4.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 5.2% +19.1pp | -13.9% -12.7pp | -1.1% +13.4pp | -14.5% -5.7pp | -8.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $2.0M +984.5% | $187.0K +111.0% | -$1.7M -2559.4% | $69.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $5.0M +130.2% | -$16.4M -2592.3% | $660.0K +107.8% | -$8.5M -75.0% | -$4.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | 3.7% +17.7pp | -14.0% -14.7pp | 0.7% +15.4pp | -14.6% -5.9pp | -8.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +133.3% | -$0 -2281.8% | $0 +106.1% | -$0 -59.1% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +125.0% | -$0 -2407.7% | $0 +105.8% | -$0 -59.1% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $139.5M +4.4% | $133.7M +12.2% | $119.1M +26.6% | $94.1M +10.1% | $85.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $150.0M +12.3% | $133.7M +5.4% | $126.8M +34.8% | $94.1M +10.1% | $85.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Apyx Medical Corporation
NASDAQ:APYX
$169.17M
Quipt Home Medical Corp.
QIPT
$162.30M
FONAR Corporation
NASDAQ:FONR
$117.76M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$106.91M
AVITA Medical, Inc.
NASDAQ:RCEL
$98.50M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$77.27M
Vivani Medical, Inc.
NASDAQ:VANI
$68.83M
eXoZymes, Inc.
NASDAQ:EXOZ
$62.62M
Estrella Immunopharma, Inc.
ESLA
$43.68M
InspireMD, Inc.
NSPR
$33.26M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does XTNT generate?
Xtant Medical Holdings, Inc. (XTNT) reported $133.93M of revenue in fiscal 2025.
Is XTNT profitable?
Xtant Medical Holdings, Inc. (XTNT) reported $4.97M of net income, with a net margin of 3.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.